- Broadens Patent Protection of PrintRite3D® In-Process Quality Assurance Platform
SANTA FE, NM – February 5, 2019 – Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/276,452, “Optical Manufacturing Process Sensing and Status Indication System.” The patent application covers a system of sensors configured to measure optical emissions generated by a scanning heat source during an additive manufacturing (AM) process and to analyze the data collected.
John Rice, CEO of Sigma Labs, said, “This patent allowance further enhances the depth and breadth of the patented intellectual property portfolio covering our PrintRite3D® platform. The technology covered in this patent enables Sigma to provide valuable and relevant quality status information to customers requiring high-quality AM metal products production. The USPTO has now allowed four patents pertaining to Sigma Lab’s PrintRite3D® platform, representing a wide degree of innovation and distinguishing us as a leader in this space. Additionally, there are eighteen more patents-pending in process.”
Mr. Rice concluded, “Sigma’s patent portfolio, our newly launched platform, and our recently signed agreements cumulatively represent what we believe is a formidable and valuable initiative through which we can more easily work with customers that need to secure a greater measure of repeatable high-quality yields and efficiency in the serial AM production of metal components.”
About Sigma Labs
Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on April 17, 2018 and which may be viewed at http://www.sec.gov.
Source:Sigma Labs, Inc.